EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Rebamipide for management of methotrexate-induced oral ulcers: a three-arm randomized clinical trial

Amira Abdelaziz, Rehab Nabil Shamma, Hala Lotfy Fayed, Shereen Ali

Clinical Oral Investigations · 2025

DOI: 10.1007/s00784-025-06159-x ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Oral Investigations, 2025. Verfasst von Amira Abdelaziz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Giza, Egypt. Hauptthemen laut MEDLINE: Alanine, Quinolones, Methotrexate, Oral Ulcer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cairo University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This RCT aimed to evaluate the effect of topical Rebamipide (regular and nanoparticulated) in comparison to topical Clobetasol propionate in the management of methotrexate-induced oral ulcers in rheumatoid arthritis patients. Materials and methods Patients were divided randomly into three parallel arms: 1% Rebamipide; 1% nanoparticulated Rebamipide, Clobetasol propionate. The outcome measures included WHO oral mucositis grading, pain (NRS), ulcer size, and healing time. The data was analyzed for any statistical significance.

Results

Intragroup comparisons of mucositis grade improvement and pain reduction revealed significant differences in all the groups. All intergroup comparisons demonstrated non-significant difference, yet nanoparticulated Rebamipide was leading, and all group participants achieved complete healing earlier than the other groups.

Conclusion

Rebamipide, regular and nanoparticulated forms, showed comparable results to potent Corticosteroid, Clobetasol propionate in management of the oral ulcers. Clinical relevance Rebamipide is an efficient promising alternative modality for management of methotrexate-induced oral ulcers in rheumatoid arthritis patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlanineQuinolonesMethotrexateOral UlcerAnti-Ulcer AgentsAntirheumatic AgentsHumansMaleFemaleMiddle AgedTreatment OutcomeClobetasolArthritis, RheumatoidAgedAdultAdministration, Topical

Stichwörter der Autor:innen

CorticosteroidMethotrexateNanoparticlesOral ulcersRebamipideRheumatoid arthritis

Substanzen

rebamipideAlanineQuinolonesMethotrexateClobetasolAnti-Ulcer AgentsAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Giza, Egypt.
  • Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Giza, Egypt.
  • Department of Rheumatology & Rehabilitation, Faculty of Medicine, Cairo University, Giza, Egypt.
  • Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Giza, Egypt. shereen.ali@dentistry.cu.edu.eg.
  • Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, 11 El-Saraya Street, Manial, 11553, Cairo, Egypt. shereen.ali@dentistry.cu.edu.eg.

Förderung

  • Cairo University

Zitieren

APA

Abdelaziz, A., Shamma, R. N., Fayed, H. L., & Ali, S. (2025). Rebamipide for management of methotrexate-induced oral ulcers: a three-arm randomized clinical trial. Clinical Oral Investigations. https://doi.org/10.1007/s00784-025-06159-x

Vancouver

Abdelaziz A, Shamma RN, Fayed HL, Ali S. Rebamipide for management of methotrexate-induced oral ulcers: a three-arm randomized clinical trial. Clinical Oral Investigations. 2025. doi:10.1007/s00784-025-06159-x

BibTeX
@article{Abdelaziz2025,
  author = {Abdelaziz, Amira and Shamma, Rehab Nabil and Fayed, Hala Lotfy and Ali, Shereen},
  title = {Rebamipide for management of methotrexate-induced oral ulcers: a three-arm randomized clinical trial},
  journal = {Clinical Oral Investigations},
  year = {2025},
  doi = {10.1007/s00784-025-06159-x}
}
Kostenlos starten →